CASE III NEOVASCULAR GLAUCOMA. Patient History 68 year old white female. Ocular History: CRAO, 2003. Medical history: Diabetes Renal Problems.

Slides:



Advertisements
Similar presentations
Emily Deschler, MD Charleen Chu, MD, PhD March 2011
Advertisements

Evan (Jake) Waxman MD PhD
Debilitating Eye Diseases
DIABETIC RETINOPATHY Diabetic retinopathy is a frequent cause of blindness. The exact cause of diabetic microvascular disease is unknown.
Clinicopathologic Case
Acute Glaucoma Conditions Acute Eye Conditions Course Dr. Sonya Bennett May 2011.
Bilateral Eviscerations-Retinopathy of Prematurity
DIABETIC RETINOPATHY.
Uveal Tract Diseases.
Anti VEGF Options in the management of CNV 1)Observation  occult CNV also requires close follow – up.every 3 month 2) Laser coagulation 3) Surgery.
J Glaucoma Volume 20, Number 5, June/July 2011 R1 何元輝 2011/09/15 EBM discussion.
Neovascular Glaucoma (NVG) Saleh A. Al-Obeidan, MD Department of Ophthalmology College of Medicine King Saud University.
ESSAM OSMAN,FRCS ASSISTANT PROFESSOR,CONSULTANT DEPATMENT OF OPHTHALMOLOGY K.S.U.
OPHTHALMOLOGY UPDATE Ajay Bhatnagar Consultant Ophthalmologist
Iris, ciliary body and choroid. Iris  The iris lies in front of the lens and the ciliary body  It separates the anterior chamber from the posterior.
Diabetic Retinopathy Steven Sanislo, M.D. Assistant Professor Stanford University Department of Ophthalmology.
The Canadian Association of Optometrists
Occlusive vascular disorders of the retina Ayesha S abdullah
Barrow, Brantley, Fredde, Gillispie
Agents Used in the Treatment of Conditions of the Eye
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute of Ophthalmology ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute.
Diabetes and the Eyes Kenyon Anderson, O.D.. Blindness Risk Diabetic eye disease, caused by diabetes, is a leading cause of blindness and vision loss.
Ocular Ischaemic Syndrome Dr Gulrez Ansari Department of Ophthalmology Watford General Hospital 3 rd November 2004.
Painful diminution of vision
Josephine-Liezl Cueto, M.D.* Kendall R. Dobbins, M.D.* Geisinger Medical Center, Department of Ophthalmology Danville, PA *No financial interest.
Adult Medical-Surgical Nursing Neurology Module: Glaucoma.
CASE IV CORNEAL HYDROPS.
Acute and Chronic visual loss By Dr. ABDULMAJID ALSHEHAH Ophthalmology consultant Anterior Segment and Uveitis consultant.
Bowman’s layer Descemet’s membrane. Pathologic Diagnosis Diagnosis – Pseudophakic bullous keratopathy with Chronic bullous keratopathy Degenerative pannus.
Grand Rounds Joseph Reck VAMC Wilkes-Barre, PA November 3, 2006.
An 80 year old women complains of a very painful eye along with a feeling of nausea of 2 days duration. On examination the eye is red. 1.What condition.
Mohamed Abdelzaher M.Sc. FOURTH YEAR BRAIN STORMING.
ACUTE VISUAL LOSS Saeed Al-Wadani, MD Assistant Professor
Eyes.
قسم طب وجراحة العيون مقدمة في طب وجراحة العيون 432 عين.
Siderosis Bulbi Zamzam Al-baker,MD Consultant Opthalmology
Ki-Cheol Chang, MD Department of Ophthalmology, Dankook University Hospital, South Korea Financial disclosure : Author has no commercial associations.
Relationship Between Postphaco TASS and U/S Tip and Sleeve Lumen
Tashkent Medical Academy
Chronic Visual Loss. CHRONIC VISUAL LOSS 1. Measure intraocular pressure with a tonometer 2. Evaluate the nerve head 3. Evaluate the clarity of the lens.
ANGLE-CLOSURE GLAUCOMA
Diffuse infiltrating retinoblastoma > >. Ocular and General History  5 years old boy  Unremarkable birth history (BBW: 2800g, full-term)  No preceding.
ANGLE-CLOSURE GLAUCOMA RISK FACTORS AND PATHOGENESIS SPEAKER: KUMAR SAURABH.
Panuveitis Mamta Agarwal Senior Consultant Uveitis & Cornea Services Sankara Nethralaya Chennai.
Dr. G. Rajasekhar MBBS, DNB, FRCS (Glasgow).  IOP  Angle  POAG  PACG  Acute congestive glaucoma  Drugs.
Glaucoma.
ANTI-VEGF Recent Advances in DR. VEGF- Vascular Endothelial Growth factor is an important growth factor for angiogenesis and is necessary for normal angiogenesis.
SPOT DIAGNOSIS DARINDA ROSA R2.
Sympathetic Ophthalmitis Annie Mathai, Rajeev K Reddy, Hemant S Trehan, Ritesh Narula Smt.Kanuri Santhamma Retina Vitreous Centre, Kallam Anji Reddy Campus,
Glaucoma Madhav Vempali Vempali Medical Ltd. Glaucoma The healthy eye Light rays enter the eye through the cornea, pupil and lens. These light rays are.
ACUT ANGLE CLOSURE GLAUCOMA
BRVO. Present by Sattar Heidari MD General ophthalmologist.
1- Dx : Cataract. 2- Management: Referral to ophthalmologist. 2-Prevention:  sunglasses  Control of diabetes.  Avoid the use of topical steroids. Answer.
A Deeper Look at Sight Threatening Conditions: Glaucoma, Macular Degeneration, and Diabetic Retinopathy Ashley S. Reddell, OD, FCOVD HOACLS 2015.
Old Fibrotic Vascular tissue in End-Stage Proliferative Retinopathy
How Diabetes Steals Vision from Your Patients
(Relates to Chapter 22, “Nursing Management: Visual and Auditory Problems,” in the textbook) Copyright © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier.
OVD of the retina CRAO Hypertensive retinopathy Ayesha S abdullah
Primary angle-closure glaucoma
Dr.Ravi kant Associate Professor Medicine ,AIIMS Rishikesh
Ocular Manifestations of Diabetes
Acute Visual Loss Saeed Alwadani, MD Assistant Professor
Ocular ischemic syndrome
DIABETIC RETINOPATHY Süleyman ÖZEN.
SECONDARY GLAUCOMAS Dr. Shinisha Paul.
NeoVascular Glaucoma Ap.최진아/R2 이기일
Overview of Common Eye Conditions
Glaucoma Clinical features and management
Presentation transcript:

CASE III NEOVASCULAR GLAUCOMA

Patient History 68 year old white female. Ocular History: CRAO, Medical history: Diabetes Renal Problems.

Recent Exam Findings July 2004 VA- 20/25, OU. Cup-to-disc;.4/.4,OU. July 2005 VA- 20/25, OD, 20/60, OS. Cup-to-disc;.6/.6, OD..9/.9, OS.

Present Exam Findings VA- OD- 20/25 OS- NLP PERRL + APD, OS. TA- 16, OD 67, OS

Observations, OS

Neovascular Glaucoma Elevation of IOP. Painful red eye. Closure of anterior chamber angle from fibrovascular membrane formation.

Causes Central retinal artery occlusion % of NVG cases. Diabetic retinopathy. Carotid artery occlusive disease. Chronic retinal detachments Usually occurs within 90 days of antecedent vascular occlusion.

Signs/Symptoms Acute onset of redness, pain, and blurred vision. Circumcilliary injection. Corneal edema. Deep anterior chamber with moderate flare. NVI/NVA.

Pathophysiology Stimulus= Lack of Oxygen. Hypoxic retinal tissue results in the release of vasoproliferative factors, i.e. VEGF. VEGF acts upon endothelial cells of viable capillaries to stimulate the formation of a new vessels. Once released, the angiogenic factors diffuse through the vitreous and posterior chamber into the aqueous and the anterior segment.

Pathophysiology, II Vasogenic factors interact with vascular structures where the greatest aqueous- tissue contact occurs. The result is new vessel growth at the pupillary border and iris surface and over the iris angle. Ultimately leading to formation of fibrovascular membranes.

Pathophysiology, III The neovascularization, along with its fibrovascular support membrane, acts to both physically block the angle and bridge the angle The vessels pull the iris and cornea into apposition, thus blocking the trabecular meshwork.

Stage I, Early Small, dilated capillaries at pupillary margin. Vessel arborization onto iris near pupil. Normal IOP.

Stage II, Mid-Phase Involvement of anterior chamber angle. Radial vessel progression. Hyphema. Increase in IOP.

Stage III, Late Contraction of the fibrovascular membrane. 360 o angle closure. Ectropion uvea. Significant anterior chamber reaction.

Management Medically treating neovascular glaucoma is like arranging deck chairs on the Titanic. Medical consult to rule out systemic disease. Duplex/Doppler scans to r/o carotid occlusive disease.

Medical Management If there is any degree of inflammation and ocular pain, prescribe a topical cycloplegic such as atropine 1% b.i.d. as well as a topical steroid such as Pred Forte.

IOP Control Medical therapy with topical ß-adrenergic antagonists, a-2 agonists, and topical or oral carbonic inhibitors lower IOP. Aqueous suppressants may be used in order to temporarily reduce IOP. However, chronic medical therapy is not indicated for neovascular glaucoma. Aqueous suppressants will temporize IOP and angle closure will continue.

Medical Management, II Ultimate management of NVG involves eradication of the vessels with PRP or cryo. Goal: destroy ischemic retina, minimize oxygen demand of the eye, and reduce the amount of VEGF being released. If a significant amount of the angle is in permanent synechial closure, filtering surgery must then be employed.

However… What if the patient is, like ours, blind? The primary goal of treatment in this stage is pain control. For blind, painful eyes with uncontrollable IOP, options include continued medical therapy, cyclodestruction, retro bulbar alcohol injection, or enucleation.

But… Our patient was also not in pain. Plan of action: Retinal consult. Possible PRP to save cornea from decompensation.

Future Possibilities Anti-VEGF therapy. VEGF appears to produce its effect partly by being proinflammatory, leading to leukocyte adhesion and inflammation. VEGF can induce injury to the endothelium, cause fenestrations in endothelial cells, and cause breakdown of tight junctions.

Pointers… Retinal artery occlusions develop NVG in only 17 percent of cases and typically within four weeks post-occlusion. Miotics are contraindicated in any case where there is active inflammation. Prostaglandin analogs should likewise be avoided.